![]() Read the full story by clicking on this headline.. |
An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a second effective treatment for the brain-wasting disease. The drug, donanemab, met all... |
0 Comments
Leave a Reply. |
NewsMaxA conservative American news and opinion website founded by Christopher Ruddy in 1998 & operated by Newsmax Media. Archives
June 2023
Categories |